Besançon, France – January 25th, 2021 – MED’INN’PHARMA announced today that it received approval from the French regulatory agency ANSM through a resubmission file concerning the CMC aspects of production of its lead candidate SuperMApo and the preclinical and clinical development plans. MIP will thus proceed to the production pilot batches dedicated to stability and tox studies before the production of a clinical batch by the end of 2021. Once done, MIP will be able to complete the IMPD file related to its lead candidate SuperMApo to enter into clinical evaluation in 2022.
About MED’INN’PHARMA – MIP, a French pharma biotechnology company funded in 2017, is a leader in the development of bio-identic drugs with pro-resolutive properties for the treatment of acute and chronic inflammatory situations. MIP’ first-in-class proprietary therapeutic lead candidates have the potential for broad applications in Immunology, infectious diseases, pulmonary, neuroscience, cardiology, metabolic and regenerative medicines. The company develops SuperMApo bio-identic drug candidate (license granted by INSERM-EFS-UBFC) with high pro-resolutive properties through a deep reeducation of the whole immune system.